MENU
+Compare
RPRX
Stock ticker: NASDAQ
AS OF
Feb 4, 02:46 PM (EDT)
Price
$43.64
Change
+$0.67 (+1.56%)
Capitalization
18.36B

RPRX stock forecast, quote, news & analysis

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties... Show more

RPRX
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. RPRX showed earnings on November 05, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for RPRX with price predictions
Feb 03, 2026

Aroon Indicator for RPRX shows an upward move is likely

RPRX's Aroon Indicator triggered a bullish signal on February 03, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 199 similar instances where the Aroon Indicator showed a similar pattern. In of the 199 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 23, 2026. You may want to consider a long position or call options on RPRX as a result. In of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RPRX just turned positive on January 26, 2026. Looking at past instances where RPRX's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

RPRX moved above its 50-day moving average on January 21, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RPRX advanced for three days, in of 288 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RPRX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RPRX broke above its upper Bollinger Band on January 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.862) is normal, around the industry mean (27.519). P/E Ratio (24.554) is within average values for comparable stocks, (51.491). Projected Growth (PEG Ratio) (1.892) is also within normal values, averaging (1.893). Dividend Yield (0.021) settles around the average of (0.043) among similar stocks. P/S Ratio (10.471) is also within normal values, averaging (331.843).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. RPRX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RPRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Dividends

RPRX paid dividends on September 10, 2025

Royalty Pharma plc RPRX Stock Dividends
А dividend of $0.22 per share was paid with a record date of September 10, 2025, and an ex-dividend date of August 15, 2025. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.23B. The market cap for tickers in the group ranges from 58 to 118.13B. VRTX holds the highest valuation in this group at 118.13B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -2%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 33%. ANL experienced the highest price growth at 161%, while QNCX experienced the biggest fall at -96%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 1%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was -6%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 81
Price Growth Rating: 58
SMR Rating: 92
Profit Risk Rating: 94
Seasonality Score: -22 (-100 ... +100)
View a ticker or compare two or three
RPRX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a provider of drug development services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
110 East 59th Street
Phone
+1 212 883-0200
Employees
89
Web
https://www.royaltypharma.com